Global Information
회사소개 | 문의 | 위시리스트

세계의 Drug Discovery 시장 예측

Global Drug Discovery Market Forecast 2019-2027

리서치사 Inkwood Research
발행일 2019년 08월 상품 코드 607157
페이지 정보 영문 167 Pages
가격
US $ 2,500 ₩ 3,036,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.
US $ 3,000 ₩ 3,643,000 PDF (Multi User License) help
동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. PDF 파일은 Copy & Paste가 되지 않습니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,465,000 PDF (Enterprisewide License) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 Drug Discovery 시장 예측 Global Drug Discovery Market Forecast 2019-2027
발행일 : 2019년 08월 페이지 정보 : 영문 167 Pages

세계의 Drug Discovery 시장에 대해 조사했으며, 시장 개요, 기술·지역별 시장 동향, 시장 규모 추정과 예측, 시장 성장 촉진·저해요인 및 시장 기회·과제 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 전해드립니다.

제1장 조사 범위

제2장 조사 방법

제3장 주요 요약

  • 시장 개요
  • 주요 조사 결과

제4장 시장 결정요인

  • 시장 성장 촉진요인
  • 시장 성장 저해요인
  • 시장 기회
  • 해결해야 할 과제

제5장 세계의 Drug Discovery 시장 : 시장 세분화

  • 기술별
    • 정량 중합효소연쇄반응(Q-PCR)
    • DNA 마이크로어레이
    • 단백질 마이크로어레이
    • HTS(High Throughput Screening)
    • 질량분석(MS)
    • 겔전기영동
    • 크로마토그래피
    • 핵산 및 단백질 분리
    • 기타 기술

제6장 주요 분석

  • Porter's Five Forces 분석
  • 밸류체인 분석
  • PESTEL 분석
  • 시장 기회 매트릭스

제7장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 기타
  • 아시아태평양
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 기타
  • 기타 지역

제8장 기업 개요

  • ASTRAZENECA PLC
  • BAYER AG
  • BOEHRINGER INGELHEIM
  • ELI LILY
  • F. HOFFMANN-LA ROCHE LTD
  • GLAXOSMITHKLINE LLC
  • JOHNSON AND JOHNSON
  • MERCK & CO. INC.
  • PFIZER, INC.
  • SANOFI

도표

KSM 18.03.08

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

LIST OF TABLES

  • TABLE 1 GLOBAL DRUG DISCOVERY MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 2 FACT SHEET OF GLOBAL FATALITIES
  • TABLE 3 GLOBAL DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2019-2027 ($ MILLION)
  • TABLE 4 GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 5 GLOBAL BIOCHIPS MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 6 GLOBAL BIOINFORMATICS MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 7 GLOBAL PHARMACOGENOMICS AND PHARMACOGENETICS MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 8 GLOBAL COMBINATORIAL CHEMISTRY MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 9 GLOBAL NANOTECHNOLOGY MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 10 GLOBAL SPECTROSCOPY MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 11 GLOBAL METABOLOMICS MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 12 GLOBAL OTHER TECHNOLOGIES MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 13 GLOBAL DRUG DISCOVERY MARKET, BY DRUG TYPE, 2019-2027 ($ MILLION)
  • TABLE 14 GLOBAL SMALL MOLECULE DRUG MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 15 GLOBAL BIOLOGIC DRUG MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 16 GLOBAL DRUG DISCOVERY MARKET, BY SERVICE, 2019-2027 ($ MILLION)
  • TABLE 17 GLOBAL DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 18 GLOBAL CHEMICAL SERVICES MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 19 GLOBAL BIOLOGICAL SERVICES MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 20 GLOBAL OTHER PHARMACEUTICAL SERVICES MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 21 GLOBAL DRUG DISCOVERY MARKET, BY END USER, 2019-2027 ($ MILLION)
  • TABLE 22 GLOBAL RESEARCH INSTITUTES MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 23 GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 24 GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 25 GLOBAL OTHER END USER MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 26 GLOBAL DRUG DISCOVERY MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 27 NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)
  • TABLE 28 EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)
  • TABLE 29 ASIA PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)
  • TABLE 30 REST OF WORLD DRUG DISCOVERY MARKET, BY REGION, 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL DRUG DISCOVERY MARKET, BY REGION, 2019-2027 ($ MILLION)
  • FIGURE 2 GLOBAL DRUG DISCOVERY MARKET, SHARE BY TECHNOLOGY 2018 & 2027 (%)
  • FIGURE 3 GLOBAL DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2019-2027 ($ MILLION)
  • FIGURE 4 GLOBAL DRUG DISCOVERY MARKET, BY BIOCHIPS, 2019-2027 ($ MILLION)
  • FIGURE 5 GLOBAL DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2019-2027 ($ MILLION)
  • FIGURE 6 GLOBAL DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2019-2027 ($ MILLION)
  • FIGURE 7 GLOBAL DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2019-2027 ($ MILLION)
  • FIGURE 8 GLOBAL DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2019-2027 ($ MILLION)
  • FIGURE 9 GLOBAL DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2019-2027 ($ MILLION)
  • FIGURE 10 GLOBAL DRUG DISCOVERY MARKET, BY METABOLOMICS, 2019-2027 ($ MILLION)
  • FIGURE 11 GLOBAL DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2019-2027 ($ MILLION)
  • FIGURE 12 GLOBAL DRUG DISCOVERY MARKET, SHARE BY DRUG TYPE 2018 & 2027 (%)
  • FIGURE 13 GLOBAL DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2019-2027 ($ MILLION)
  • FIGURE 14 GLOBAL DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2019-2027 ($ MILLION)
  • FIGURE 15 GLOBAL DRUG DISCOVERY MARKET, SHARE BY SERVICE 2018 & 2027 (%)
  • FIGURE 16 GLOBAL DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES 2019-2027 ($ MILLION)
  • FIGURE 17 GLOBAL DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 18 GLOBAL DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 19 GLOBAL DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 20 GLOBAL DRUG DISCOVERY MARKET, SHARE BY END USER 2018 & 2027 (%)
  • FIGURE 21 GLOBAL DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2019-2027 ($ MILLION)
  • FIGURE 22 GLOBAL DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2019-2027 ($ MILLION)
  • FIGURE 23 GLOBAL DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), 2019-2027 ($ MILLION)
  • FIGURE 24 GLOBAL DRUG DISCOVERY MARKET, BY OTHER END USER, 2019-2027 ($ MILLION)
  • FIGURE 25 PORTER'S FIVE FORCE MODEL
  • FIGURE 26 GLOBAL DRUG DISCOVERY MARKET, REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 27 THE UNITED STATES DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 28 CANADA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 29 THE UNITED KINGDOM DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 30 FRANCE DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 31 GERMANY DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 32 SPAIN DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 33 ITALY DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 34 REST OF EUROPE DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 35 CHINA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 36 INDIA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 37 JAPAN DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 38 SOUTH KOREA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 39 AUSTRALIA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 40 REST OF ASIA PACIFIC DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 41 LATIN AMERICA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 42 MIDDLE EAST AND AFRICA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

KEY FINDINGS

The global drug discovery market is expected to rise at a CAGR of 8.54% during the forecast period of 2019-2027. In terms of revenue, the global market accounted for $XX million in 2018 and is estimated to reach $83155 million by 2027. The market is primarily driven by factors like rising incidences of chronic diseases across the globe and increasing government funding to various research & development programs.

MARKET INSIGHTS

The global drug discovery market is classified into several segments, such as technology, services, end-users, and drug type. The applications of small molecule drugs in the treatment of chronic disorders is primarily surging the demand for drugs in the market. The rising technological developments and innovations are fueling the drug discovery market at a significant pace. Also, many drug manufacturers, government, and private players are investing in the research & development activities, which further enlarge the global drug discovery market.

REGIONAL INSIGHTS

North America, Asia-Pacific, Europe and Rest of World are the geographical segments of the drug discovery market. By the end of the forecast period, the North American market is anticipated to account for the lion's share of the global market. The U.S is expected to be one of the major contributors to this region owing to high healthcare spending and growing lifestyle-related diseases. Also, the Asia-Pacific market is predicted to register the fastest growth driven by high investments and growing R&D.

COMPETITIVE INSIGHTS

Noted players in the global drug discovery market include AstraZeneca PLC, Pfizer Inc., 3M Company, Antares Pharma, Becton, Dickinson & Company (BD), Eli Lily, Johnson and Johnson, F. Hoffmann-La Roche Ltd., Bayer AG, Boehringer Ingelheim, Novartis, Merck & Co. Inc., Sanofi, and GlaxoSmithKline LLC.

Table of contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. HIGH PREVALENCE RATES OF MAJOR HEALTH DISORDERS
    • 3.2.2. IMPLEMENTATION OF DRUG DISCOVERY PROGRAMS
    • 3.2.3. BIOINFORMATICS IS THE WIDELY USED DRUG DISCOVERY TECHNOLOGY
    • 3.2.4. SMALL MOLECULE DRUG TYPE CONSTITUTES THE HIGHEST MARKET SHARE
    • 3.2.5. CONTRACT RESEARCH ORGANIZATIONS (CROS) ARE THE FASTEST-GROWING END USER

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. AGING POPULATION
    • 4.2.2. BRANDED DRUGS ARE OUTPERFORMING DUE TO HIGH COST COMPARED TO GENERIC DRUGS
    • 4.2.3. GROWING HEALTHCARE EXPENDITURE
    • 4.2.4. GLOBAL INCREASE IN LIFESTYLE ORIENTED DISEASES & FATALITIES
    • 4.2.5. TECHNOLOGICAL ADVANCEMENT
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. DELAY IN PRODUCT LAUNCHES
    • 4.3.2. POOR ACCESS TO HEALTHCARE SERVICES IN DEVELOPING MARKETS
    • 4.3.3. SHIFT FROM BRANDED TO GENERIC DRUGS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. EXTENSIVE R & D FOR NEW PRODUCT LAUNCHES
    • 4.4.2. INCREASING DEMAND FOR SPECIALTY MEDICINES
    • 4.4.3. RISING INVESTMENT BY PHARMACEUTICAL COMPANIES IN IMPROVING BIG-DATA ANALYTICAL CAPABILITIES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. COST BARRIER FOR LOCAL PEOPLE IN EMERGING ECONOMIES
    • 4.5.2. STRINGENT GOVERNMENT REGULATIONS

5. MARKET BY TECHNOLOGY

  • 5.1. HIGH THROUGHPUT SCREENING
  • 5.2. BIOCHIPS
  • 5.3. BIOINFORMATICS
  • 5.4. PHARMACOGENOMICS AND PHARMACOGENETICS
  • 5.5. COMBINATORIAL CHEMISTRY
  • 5.6. NANOTECHNOLOGY
  • 5.7. SPECTROSCOPY
  • 5.8. METABOLOMICS
  • 5.9. OTHER TECHNOLOGIES

6. MARKET BY DRUG TYPE

  • 6.1. SMALL MOLECULE DRUG
  • 6.2. BIOLOGIC DRUG

7. MARKET BY SERVICE

  • 7.1. DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES
  • 7.2. CHEMICAL SERVICES
  • 7.3. BIOLOGICAL SERVICES
  • 7.4. OTHER PHARMACEUTICAL SERVICES

8. MARKET BY END USER

  • 8.1. RESEARCH INSTITUTES
  • 8.2. PHARMACEUTICAL COMPANIES
  • 8.3. CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 8.4. OTHER END USER

9. KEY ANALYTICS

  • 9.1. PORTER'S FIVE FORCES MODEL
    • 9.1.1. THREATS OF NEW ENTRANTS
    • 9.1.2. THREAT OF SUBSTITUTE PRODUCTS
    • 9.1.3. BARGAINING POWER OF BUYERS
    • 9.1.4. BARGAINING POWER OF SUPPLIERS
  • 9.2. COMPETITIVE RIVALRY
  • 9.3. VALUE CHAIN ANALYSIS
  • 9.4. PESTLE ANALYSIS
  • 9.5. REGULATORY FRAMEWORK
  • 9.6. OPPORTUNITY MATRIX

10. GEOGRAPHICAL ANALYSIS

  • 10.1. NORTH AMERICA
    • 10.1.1. THE UNITED STATES
    • 10.1.2. CANADA
  • 10.2. EUROPE
    • 10.2.1. THE UNITED KINGDOM
    • 10.2.2. FRANCE
    • 10.2.3. GERMANY
    • 10.2.4. SPAIN
    • 10.2.5. ITALY
    • 10.2.6. REST OF EUROPE
  • 10.3. ASIA PACIFIC
    • 10.3.1. CHINA
    • 10.3.2. INDIA
    • 10.3.3. JAPAN
    • 10.3.4. SOUTH KOREA
    • 10.3.5. AUSTRALIA
    • 10.3.6. REST OF ASIA PACIFIC
  • 10.4. REST OF WORLD
    • 10.4.1. LATIN AMERICA
    • 10.4.2. MIDDLE EAST AND AFRICA

11. COMPANY PROFILES

  • 11.1. 3M COMPANY
  • 11.2. ANTARES PHARMA
  • 11.3. ASTRAZENECA PLC
  • 11.4. BAYER AG
  • 11.5. BECTON, DICKINSON & COMPANY (BD)
  • 11.6. BOEHRINGER INGELHEIM
  • 11.7. ELI LILY
  • 11.8. F. HOFFMANN-LA ROCHE LTD
  • 11.9. GLAXOSMITHKLINE LLC
  • 11.10. JOHNSON AND JOHNSON
  • 11.11. MERCK & CO. INC.
  • 11.12. NOVARTIS
  • 11.13. PFIZER, INC.
  • 11.14. SANOFI
Back to Top
전화 문의
F A Q